Stefano Luminari

12.1k total citations · 2 hit papers
216 papers, 5.6k citations indexed

About

Stefano Luminari is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Stefano Luminari has authored 216 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 175 papers in Pathology and Forensic Medicine, 91 papers in Oncology and 61 papers in Genetics. Recurrent topics in Stefano Luminari's work include Lymphoma Diagnosis and Treatment (175 papers), Chronic Lymphocytic Leukemia Research (57 papers) and Viral-associated cancers and disorders (56 papers). Stefano Luminari is often cited by papers focused on Lymphoma Diagnosis and Treatment (175 papers), Chronic Lymphocytic Leukemia Research (57 papers) and Viral-associated cancers and disorders (56 papers). Stefano Luminari collaborates with scholars based in Italy, United States and United Kingdom. Stefano Luminari's co-authors include Massimo Federico, Francesco Merli, Luigi Marcheselli, Caterina Stelitano, Luigi Rigacci, Umberto Vitolo, Monica Bellei, Francesco Di Raimondo, Annibale Versari and Luca Baldini and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Stefano Luminari

195 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Early Interim 2-[ ¹⁸ F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study

2007 552 citations Andrea Gallamini, Martin Hutchings et al. Journal of Clinical Oncology profile →
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project

2009 506 citations Massimo Federico, Monica Bellei et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stefano Luminari Italy	35	4.3k	2.6k	1.3k	1.2k	1.1k	216	5.6k
Francesco Merli Italy	33	3.4k 0.8×	1.8k 0.7×	1.2k 0.9×	871 0.8×	1.0k 0.9×	157	4.3k
Jan Walewski Poland	31	4.6k 1.1×	4.2k 1.6×	1.4k 1.1×	1.9k 1.7×	736 0.7×	214	7.0k
Beate Pfistner Germany	16	4.3k 1.0×	2.5k 1.0×	1.6k 1.3×	1.1k 0.9×	965 0.9×	43	5.1k
Éric Van Den Neste Belgium	18	5.5k 1.3×	4.2k 1.6×	1.6k 1.2×	2.0k 1.7×	541 0.5×	46	7.2k
Luigi Rigacci Italy	28	3.1k 0.7×	1.6k 0.6×	974 0.8×	809 0.7×	798 0.7×	144	4.0k
David J. Straus United States	44	4.6k 1.1×	2.9k 1.1×	1.6k 1.3×	1.6k 1.4×	1.2k 1.1×	175	6.5k
Umberto Vitolo Italy	51	7.3k 1.7×	4.2k 1.6×	2.2k 1.8×	2.5k 2.2×	1.6k 1.5×	294	9.0k
Pauline Brice France	48	6.3k 1.5×	5.0k 1.9×	2.1k 1.6×	2.0k 1.7×	1.1k 1.0×	192	8.1k
Judith Trotman Australia	27	2.7k 0.6×	1.3k 0.5×	592 0.5×	1.3k 1.1×	576 0.5×	159	3.6k
Bernd Metzner Germany	36	3.4k 0.8×	2.9k 1.1×	1.0k 0.8×	1.6k 1.4×	1.2k 1.2×	126	5.6k

Countries citing papers authored by Stefano Luminari

Since Specialization

Citations

This map shows the geographic impact of Stefano Luminari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefano Luminari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefano Luminari more than expected).

Fields of papers citing papers by Stefano Luminari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefano Luminari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefano Luminari. The network helps show where Stefano Luminari may publish in the future.

Co-authorship network of co-authors of Stefano Luminari

This figure shows the co-authorship network connecting the top 25 collaborators of Stefano Luminari. A scholar is included among the top collaborators of Stefano Luminari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefano Luminari. Stefano Luminari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Viviani, Simonetta, Chiara Pavoni, Sally F. Barrington, et al.. (2025). Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials. Blood Cancer Journal. 15(1). 165–165.

Marchetti, Monia, Paolo Corradini, Luca Arcaini, et al.. (2025). A SWOT‐Consensus for CAR‐T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection. Hematological Oncology. 43(5). e70125–e70125.

Luminari, Stefano, Annalisa Chiappella, Alice Di Rocco, et al.. (2025). Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: A Delphi consensus. Cytotherapy. 27(11). 1316–1325.

Birhiray, Ruemu, Stefano Luminari, Tae Min Kim, et al.. (2024). Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator’s choice in previously untreated follicular lymphoma (OLYMPIA-1).. Journal of Clinical Oncology. 42(16_suppl). TPS7096–TPS7096. 2 indexed citations

Luminari, Stefano, Alexander Fosså, Judith Trotman, et al.. (2023). Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial. Journal of Clinical Oncology. 42(1). 13–18. 16 indexed citations

Luminari, Stefano & Tetiana Skrypets. (2021). What's new in peripheral T‐cell lymphomas. Hematological Oncology. 39(S1). 52–60. 4 indexed citations

Frazzi, Raffaele, et al.. (2020). Droplet digital PCR is a sensitive tool for the detection of TP53 deletions and point mutations in chronic lymphocytic leukaemia. British Journal of Haematology. 189(2). e49–e52. 16 indexed citations

Luminari, Stefano, Benedetta Donati, Massimiliano Casali, et al.. (2019). A Gene Expression–based Model to Predict Metabolic Response After Two Courses of ABVD in Hodgkin Lymphoma Patients. Clinical Cancer Research. 26(2). 373–383. 11 indexed citations

Cottereau, Anne‐Ségolène, Annibale Versari, Stefano Luminari, et al.. (2018). Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study. Blood. 131(22). 2449–2453. 52 indexed citations

10.

Luminari, Stefano, et al.. (2018). High-risk follicular lymphoma patients: Identification and treatment. IRIS UNIMORE (University of Modena and Reggio Emilia). 23(1). 19–29. 1 indexed citations

11.

Ciammella, Patrizia, Stefano Luminari, Luca Arcaini, & Andrea Riccardo Filippi. (2018). Renewed interest for low‐dose radiation therapy in follicular lymphomas: From biology to clinical applications. Hematological Oncology. 36(5). 723–732. 3 indexed citations

12.

Santi, Roberto, Manuela Ceccarelli, Chiara Monagheddu, et al.. (2016). A pooled data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL): Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in non-Hodgkin lymphoma (NHL). Annals of Oncology. 27. vi316–vi316. 1 indexed citations

13.

Solal‐Céligny, Philippe, Monica Bellei, Luigi Marcheselli, et al.. (2012). Watchful Waiting in Low–Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database. Journal of Clinical Oncology. 30(31). 3848–3853. 88 indexed citations

14.

Federico, Massimo, Stefano Luminari, Alessandra Dondi, et al.. (2012). R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: Final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL). American Journal of Clinical Oncology. 6 indexed citations

15.

Luminari, Stefano, Antonella Montanini, Dolores Caballero, et al.. (2011). patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial. Annals of Oncology. 1 indexed citations

16.

Marcos‐Gragera, Rafael, Claudia Allemani, Carmen Ţereanu, et al.. (2011). Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project. Haematologica. 96(5). 720–728. 51 indexed citations

17.

Conconi, Annarita, Giovanni Martinelli, Armando López‐Guillermo, et al.. (2010). Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). Annals of Oncology. 22(3). 689–695. 54 indexed citations

18.

Gallamini, Andrea, Martin Hutchings, Luigi Rigacci, et al.. (2007). Early Interim 2-[ ¹⁸ F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study. Journal of Clinical Oncology. 25(24). 3746–3752. 552 indexed citations breakdown →

19.

Goldaniga, Maria, Andrea Ferrario, Sergio Cortelazzo, et al.. (2005). CD5 negative chronic B cell leukemias : a polycentric retrospective study. Haematologica. 90. 119–119. 1 indexed citations

20.

Bennett, Charles L., Stefano Luminari, Allen R. Nissenson, et al.. (2004). Pure Red-Cell Aplasia and Epoetin Therapy. New England Journal of Medicine. 351(14). 1403–1408. 284 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact